PEMT Gene and Methylation | Decoding Inflammation

By Alberto Rivera, MD · 2026-06-06 · 3 min

When clinicians discuss the genomic regulation of methylation, the conversation invariably begins and ends with MTHFR. This narrow focus ignores a massive metabolic sink for methyl groups that fundamentally dictates cellular membrane integrity and epigenetic expression: the PEMT gene. Encoding the enzyme phosphatidylethanolamine N-methyltransferase, PEMT bridges the gap between lipid metabolism and the methylation cycle, serving as a critical regulator of what I classify as hepatic Geneflammation.

The PEMT Gene and De Novo Phosphatidylcholine Synthesis

Located on chromosome 17p11.2, the PEMT gene is primarily expressed in the liver. Its specific physiological role is the de novo synthesis of phosphatidylcholine (PC) from phosphatidylethanolamine (PE). While PC can be obtained via dietary choline salvage pathways, the PEMT pathway is non-negotiable for producing the specific, long-chain polyunsaturated species of PC required for optimal biliary function, very-low-density lipoprotein (VLDL) assembly, and cellular membrane fluidity.

The SAMe Sink: Epigenetic Implications

The biochemical reality of PEMT activity is staggering: the conversion of PE to PC consumes up to 70% of the liver's S-adenosylmethionine (SAMe). Because PEMT is such a massive consumer of methyl groups, polymorphisms in this gene—most notably rs7946—create a profound ripple effect across the entire epigenetic landscape. If PEMT is upregulated or inefficient, it drains the systemic SAMe pool, leaving inadequate methyl donors for DNA methyltransferases (DNMTs). This secondary hypomethylation disrupts gene silencing, potentially activating dormant pro-inflammatory genes and driving systemic Geneflammation.

Hepatic Geneflammation and NAFLD

Conversely, when PEMT function is compromised by loss-of-function single nucleotide polymorphisms, the liver cannot synthesize adequate PC. Phosphatidylcholine is an absolute requirement for the packaging and export of triglycerides into VLDL particles. Without it, triglycerides accumulate in the hepatocytes. This genetically driven hepatic steatosis is a primary catalyst for Non-Alcoholic Fatty Liver Disease (NAFLD). The retained lipids undergo peroxidation, triggering resident Kupffer cells to release inflammatory cytokines like TNF-alpha and IL-6, manifesting as severe hepatic Geneflammation.

Clinical Phenotypes and Precision Therapeutics

Women are particularly vulnerable to PEMT polymorphisms, as estrogen normally upregulates PEMT expression to meet the high choline demands of pregnancy and lactation. Post-menopausal women with the rs7946 variant are at an exponentially higher risk for NAFLD and systemic choline deficiency. Clinical intervention requires a precise, epigenetically targeted approach. We must bypass the defective de novo synthesis pathway by providing exogenous, dietary, or supplemental choline—specifically in the form of phosphatidylcholine or citicoline. By supplying the downstream product, we relieve the methylation drain, suppress hepatic lipotoxicity, and restore epigenetic homeostasis.